Giovanni Pisapia
Overview
Explore the profile of Giovanni Pisapia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leotta S, Markovic U, Pirosa M, Stella S, Tringali S, Martino M, et al.
Ann Hematol
. 2021 Mar;
100(7):1743-1753.
PMID: 33774681
The experience of third-generation tyrosine kinase inhibitor ponatinib treatment in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph'+ ALL) patients post-allogeneic transplantation is limited. We retrospectively collected data on 25 Ph'+ ALL...
2.
Pastore D, Bruno B, Carluccio P, De Candia M, Mammoliti S, Borghero C, et al.
Ann Hematol
. 2020 Feb;
99(4):867-875.
PMID: 32036421
A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT....
3.
Gaudio F, Mazza P, Mele A, Palazzo G, Carella A, Delia M, et al.
Ann Hematol
. 2019 Mar;
98(6):1449-1455.
PMID: 30868307
This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin...
4.
Gaudio F, Mazza P, Carella A, Mele A, Palazzo G, Pisapia G, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Oct;
19(1):35-40.
PMID: 30293754
Background: Hodgkin lymphoma (HL) is a potentially curable disease, and modern therapy is expected to successfully cure more than 80% of the patients. However, patients progressing after intensive treatments, such...
5.
Rossi G, Carella A, Minervini M, Di Nardo F, de Waure C, Greco M, et al.
Leuk Res
. 2014 Dec;
39(2):138-43.
PMID: 25498507
Minimal residual disease (MRD) of 30 adult AML patients was monitored by multiparameter flow cytometry (MFC) and WT1 expression before and after allogeneic stem cell transplantation (allo-SCT). Diagnostic performance of...
6.
Girmenia C, Raiola A, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al.
Biol Blood Marrow Transplant
. 2014 Mar;
20(6):872-80.
PMID: 24631738
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano...
7.
Rossio R, Ferrari B, Cairo A, Mancini I, Pisapia G, Palazzo G, et al.
Blood Transfus
. 2012 Oct;
11(2):241-4.
PMID: 23058857
Background: Thrombotic thrombocytopenic purpura is a rare, life-threatening disease characterised by microangiopathic haemolytic anaemia, thrombocytopenia and symptoms related to organ ischaemia, mainly involving the brain and the kidney. It is...